Aligos Therapeutics, Inc. Proceeds from Stock Plans
Aligos Therapeutics, Inc. (ALGS) reported Proceeds from Stock Plans of $236.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromStockPlans · last filed 2026-08-06
- Aligos Therapeutics, Inc. proceeds from stock plans for the quarter ending 2025-12-31 was $124.00K, a 10.79% decline year-over-year.
- Aligos Therapeutics, Inc. proceeds from stock plans for the quarter ending 2025-09-30 was $0.00.
- Aligos Therapeutics, Inc. proceeds from stock plans for the quarter ending 2024-12-31 was $139.00K, a 54.44% increase year-over-year.
- Aligos Therapeutics, Inc. proceeds from stock plans for the quarter ending 2024-09-30 was $0.00.
- Aligos Therapeutics, Inc. proceeds from stock plans for fiscal 2025 was $304.00K, a 30.28% decline from fiscal 2024.
- Aligos Therapeutics, Inc. proceeds from stock plans for fiscal 2024 was $436.00K, a 20.87% decline from fiscal 2023.
- Aligos Therapeutics, Inc. proceeds from stock plans for fiscal 2023 was $551.00K, a 168.78% increase from fiscal 2022.
- Aligos Therapeutics, Inc. proceeds from stock plans for fiscal 2022 was $205.00K.
| Period end | Proceeds from Stock Plans 3 month | Proceeds from Stock Plans 6 month | Proceeds from Stock Plans 9 month | Proceeds from Stock Plans 12 month |
|---|---|---|---|---|
| 2026-06-30 | $236.00K 10-Q · filed 2026-08-06 | |||
| 2025-12-31 | $124.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $124.00K derived: sum of 2 quarters · filed 2026-03-05 | $304.00K 10-K · filed 2026-03-05 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $180.00K 10-Q · filed 2025-11-06 | ||
| 2025-06-30 | $180.00K 10-Q · filed 2026-08-06 | |||
| 2024-12-31 | $139.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $139.00K derived: sum of 2 quarters · filed 2026-03-05 | $436.00K 10-K · filed 2026-03-05 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $297.00K 10-Q · filed 2025-11-06 | ||
| 2024-06-30 | $297.00K 10-Q · filed 2025-08-06 | |||
| 2023-12-31 | $90.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $90.00K derived: sum of 2 quarters · filed 2025-03-10 | $551.00K 10-K · filed 2025-03-10 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $461.00K 10-Q · filed 2024-11-06 | ||
| 2023-06-30 | $461.00K 10-Q · filed 2024-08-06 | |||
| 2022-12-31 | $94.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $94.00K derived: sum of 2 quarters · filed 2024-03-12 | $205.00K 10-K · filed 2024-03-12 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $111.00K 10-Q · filed 2023-11-02 | ||
| 2022-06-30 | $111.00K 10-Q · filed 2023-08-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |